Given the high immunogenicity of the mutations, and the identification of CALRmut specific T-cell memory responses in healthy donors (9), which suggest a defect in the tumor immune surveillance in CALRmut patients (10), we conducted a phase I clinical vaccination trial against mutant CALR (NCT 03566446) (11). Here, CALR is linked to neoplasm.